The divestiture simplifies IFF's portfolio to higher-growth Taste, Scent, and Health & Biosciences segments. The ~$3.8B cash inflow enables significant deleveraging and potential buybacks. Monitor regulatory timeline and Q2 2027 close; near-term EPS dilution is a headwind but the strategic refocusing and balance sheet improvement are positive catalysts. The reiterated 2026 guidance provides a floor for expectations.
Price Chart
Executive Summary
IFF entered into a definitive agreement to sell its Food Ingredients business to CVC Capital Partners for approximately $4.3 billion (enterprise value), representing a ~10x EBITDA multiple. IFF expects net cash proceeds of ~$3.8 billion at closing and will retain a ~9.9% minority equity interest valued at ~$200 million. The transaction is expected to close by end of Q2 2027 and is dilutive to adjusted EPS in the first 12 months post-close.
Key Financial Metrics
Key Facts
- IFF agreed to sell its Food Ingredients business to CVC Capital Partners for ~$4.3 billion enterprise value (~10x EBITDA).
- IFF expects net cash proceeds of ~$3.8 billion at closing, plus a ~9.9% minority equity interest valued at ~$200 million.
- The Food Ingredients business generated ~$3.1 billion in sales and ~$430 million in EBITDA in 2025.
- Proceeds will be prioritized for debt reduction, targeted share repurchases, and reinvestment in core businesses.
- Transaction expected to close by end of Q2 2027, subject to regulatory approvals and customary conditions.
- IFF reiterated full-year 2026 guidance: sales $10.5B-$10.8B, adjusted operating EBITDA $2.05B-$2.15B.
- Transaction is expected to be dilutive to adjusted EPS in the first 12 months following closing.
- IFF has divested 13 non-core businesses including this one, generating nearly $10 billion in gross proceeds.
Financial Impact
~$4.3 billion enterprise value; ~$3.8 billion net cash proceeds; ~$200 million retained equity stake; ~10x EBITDA multiple
Risk Factors
- Transaction expected to be dilutive to adjusted EPS in first 12 months post-close.
- Closing not expected until end of Q2 2027 — regulatory and execution risks over ~12-month period.
- Stranded overhead costs from the carve-out could pressure margins if not fully addressed.
- Retained minority stake (~10%) limits upside participation and introduces illiquidity.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-249963 |
| Document: d118591dex991.htm | 0001193125-26-249963 |
| Document: 0001193125-26-249963-index-headers.html | 0001193125-26-249963 |
| Document: 0001193125-26-249963-index.html | 0001193125-26-249963 |
| Document: 0001193125-26-249963.txt | 0001193125-26-249963 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | ANALYST-UPGRADE | $83.61 $82.96 | ▼ −0.78% | ▼ −0.56% | $83.13 (−0.57%) |
Aug 10, 2026 7w ago | Insider Cluster | $85.00 $81.00 | ▼ −4.71% | ▼ −4.30% | $83.13 (−2.20%) |
Jul 20, 2026 10w ago | Press Release | $76.26 $76.40 | ▲ +0.18% | ▲ +1.41% | $83.13 (+9.01%) |
Jun 23, 2026 14w ago | 8-K | $75.83 $81.15 | ▲ +7.02% | ▲ +5.31% | $83.13 (+9.63%) |
Jun 9, 2026 16w ago | ANALYST-UPGRADE | $75.78 $78.36 | ▲ +3.40% | ▲ +0.99% | $83.13 (+9.70%) |
Jun 1, 2026 17w ago | 8-K | $74.26 $73.01 | ▼ −1.68% | ▲ +1.07% | $83.13 (+11.94%) |
Mar 18, 2026 28w ago | DEFA14A | $67.91 $70.71 | ▲ +4.12% | ▲ +4.84% | $83.13 (+22.41%) |
Mar 12, 2026 29w ago | Insider Cluster | $69.60 $67.73 | ▼ −2.69% | ▼ −1.71% | $83.13 (+19.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access